Puma Biotechnology, Inc.
US ˙ NasdaqGS ˙ US74587V1070

SecurityPBYI / Puma Biotechnology, Inc.
InstitutionSquarepoint Ops LLC
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Squarepoint Ops LLC closes position in PBYI / Puma Biotechnology, Inc.

On February 13, 2026 - Squarepoint Ops LLC filed a 13F-HR form disclosing ownership of 0 shares of Puma Biotechnology, Inc. (US:PBYI) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 21,334 shares of Puma Biotechnology, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F PUMA BIOTECHNOLOGY COM 74587V107 0 -100.00 0
2025-11-14 2025-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 21,334 3,540 19.89 113 85.25 0.0001
2025-08-27 2025-06-30 13F/A-1 PUMA BIOTECHNOLOGY COM 74587V107 17,794 17,794 61 0.0001
2025-08-14 2025-06-30 13F PUMA BIOTECHNOLOGY COM 74587V107 17,794 17,794 61 0.0001
2025-08-27 2025-03-31 13F/A-1 PUMA BIOTECHNOLOGY COM 74587V107 0 -75,929 -100.00 0 -100.00
2025-05-15 2025-03-31 13F PUMA BIOTECHNOLOGY COM 74587V107 0 -75,929 0
2025-02-14 2024-12-31 13F PUMA BIOTECHNOLOGY COM 74587V107 75,929 -23,318 -23.49 232 -8.70 0.0002
2024-11-14 2024-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 99,247 27,856 39.02 253 9.05 0.0004
2024-08-14 2024-06-30 13F PUMA BIOTECHNOLOGY COM 74587V107 71,391 10,757 17.74 233 -27.73 0.0004
2024-05-15 2024-03-31 13F PUMA BIOTECHNOLOGY COM 74587V107 60,634 32,236 113.52 321 163.11 0.0006
2024-02-14 2023-12-31 13F PUMA BIOTECHNOLOGY COM 74587V107 28,398 -28,180 -49.81 123 -17.57 0.0002
2023-11-14 2023-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 56,578 -34,409 -37.82 149 -53.89 0.0004
2023-08-14 2023-06-30 13F PUMA BIOTECHNOLOGY COM 74587V107 90,987 74,137 439.98 321 517.31 0.0010
2023-05-15 2023-03-31 13F PUMA BIOTECHNOLOGY COM 74587V107 16,850 -1,043 -5.83 52 -30.67 0.0002
2023-02-14 2022-12-31 13F PUMA BIOTECHNOLOGY COM 74587V107 17,893 17,893 76 0.0003
2022-05-16 2022-03-31 13F PUMA BIOTECHNOLOGY COM 74587V107 0 -38,201 -100.00 0 -100.00
2022-02-14 2021-12-31 13F PUMA BIOTECHNOLOGY COM 74587V107 38,201 -61,156 -61.55 116 -83.33 0.0003
2021-11-15 2021-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 99,357 22,431 29.16 696 -1.42 0.0020
2021-08-16 2021-06-30 13F PUMA BIOTECHNOLOGY COM 74587V107 76,926 37,226 93.77 706 82.90 0.0027
2021-05-17 2021-03-31 13F PUMA BIOTECHNOLOGY COM 74587V107 39,700 -14,428 -26.66 386 -30.45 0.0023
2021-02-16 2020-12-31 13F PUMA BIOTECHNOLOGY COM 74587V107 54,128 34,425 174.72 555 178.89 0.0041
2020-11-16 2020-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 19,703 3,045 18.28 199 14.37 0.0027
2020-08-14 2020-06-30 13F PUMA BIOTECHNOLOGY COM 74587V107 16,658 16,658 174 0.0028
2020-05-15 2020-03-31 13F PUMA BIOTECHNOLOGY COM 74587V107 0 -130,773 -100.00 0 -100.00
2020-02-14 2019-12-31 13F PUMA BIOTECHNOLOGY COM 74587V107 130,773 -39,154 -23.04 1,144 -37.45 0.0068
2019-11-14 2019-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 169,927 -18,225 -9.69 1,829 -23.50 0.0163
2019-08-14 2019-06-30 13F PUMA BIOTECHNOLOGY COM 74587V107 188,152 158,862 542.38 2,391 110.48 0.0233
2019-05-15 2019-03-31 13F PUMA BIOTECHNOLOGY COM 74587V107 29,290 -1,475 -4.79 1,136 81.47 0.0120
2019-02-14 2018-12-31 13F PUMA BIOTECHNOLOGY COM 74587V107 30,765 -9,426 -23.45 626 -66.03 0.0073
2018-11-14 2018-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 40,191 40,191 1,843 0.0221
2018-05-15 2018-03-31 13F PUMA BIOTECHNOLOGY COM 74587V107 0 -10,626 -100.00 0 -100.00
2018-02-14 2017-12-31 13F PUMA BIOTECHNOLOGY COM 74587V107 10,626 1,955 22.55 1,050 1.16 0.0183
2017-11-14 2017-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 8,671 -14,263 -62.19 1,038 -48.20 0.0200
2017-08-14 2017-06-30 13F PUMA BIOTECHNOLOGY COM 74587V107 22,934 171 0.75 2,004 136.60 0.0394
2017-05-15 2017-03-31 13F PUMA BIOTECHNOLOGY COM 74587V107 22,763 -1,371 -5.68 847 14.30 0.0234
2017-02-14 2016-12-31 13F PUMA BIOTECHNOLOGY COM 74587V107 24,134 20,430 551.57 741 198.79 0.0303
2016-11-14 2016-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 3,704 3,704 0.00 248 0.0165
2015-11-16 2015-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 0 -9,627 -100.00 0 -100.00
2015-08-14 2015-06-30 13F PUMA BIOTECHNOLOGY COM 74587V107 9,627 9,627 1,124 0.3648
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.